Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Anebulo Pharmaceuticals Inc (ANEB)

Anebulo Pharmaceuticals Inc (ANEB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Anebulo Pharmaceuticals Reports Third Quarter Fiscal 2023 Financial Results and Recent Updates PR Newswire - Thu May 11, 2023

/PRNewswire/ -- Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from...

ANEB : 2.09 (+8.74%)
Ligand Reports First Quarter 2023 Financial Results Business Wire - Thu May 4, 2023

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three months ended March 31, 2023, and provided an operating forecast and business updates. Ligand management...

LGND : 103.82 (+0.19%)
TVTX : 8.98 (+4.78%)
VKTX : 64.63 (+0.44%)
NOVN : 0.0941 (-24.84%)
NVS : 118.56 (+0.68%)
ANEB : 2.09 (+8.74%)
Anebulo Pharmaceuticals Announces Positive Complete Phase 2 Clinical Data Demonstrating Potential of ANEB-001 as a Treatment for Acute Cannabinoid Intoxication PR Newswire - Tue Mar 28, 2023

/PRNewswire/ -- Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB) (the "Company" or "Anebulo"), a clinical-stage biopharmaceutical company developing novel...

ANEB : 2.09 (+8.74%)
Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2023 Financial Results and Recent Updates Business Wire - Fri Feb 10, 2023

Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse (the “Company”...

ANEB : 2.09 (+8.74%)
Anebulo Pharmaceuticals Announces Completion of Dosing and Preliminary Data from Part B of its Phase 2 Study of ANEB-001 for Acute Cannabinoid Intoxication Business Wire - Mon Jan 9, 2023

Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (“ACI”) and substance addiction...

ANEB : 2.09 (+8.74%)
Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2023 Financial Results and Recent Updates Business Wire - Thu Nov 10, 2022

Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse (the “Company”...

ANEB : 2.09 (+8.74%)
Anebulo Pharmaceuticals Announces Appointment of Nat Calloway, Ph.D., to Board of Directors Business Wire - Tue Nov 1, 2022

Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) and substance abuse disorder...

ANEB : 2.09 (+8.74%)
Anebulo Pharmaceuticals Announces $6.6 Million Private Placement Financing Business Wire - Mon Sep 26, 2022

Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction...

ANEB : 2.09 (+8.74%)
Anebulo Pharmaceuticals Announces Positive Interim Data for ANEB-001 from Part B of its Phase 2 Clinical Trial for Acute Cannabinoid Intoxication Business Wire - Mon Sep 26, 2022

Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction...

ANEB : 2.09 (+8.74%)
Anebulo Pharmaceuticals to Webcast R&D Day on September 26, 2022 Business Wire - Tue Sep 20, 2022

Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) and substance abuse disorder...

ANEB : 2.09 (+8.74%)

Barchart Exclusives

MSFT vs. ORCL: Which AI Software Stock is a Better Buy? Barchart - Sat Aug 24, 10:30AM CDT
Microsoft and Oracle have been leaders in developing market-leading AI software. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot